Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Carlos Roncero, Jose Luis Villegas, Maria Martínez-Rebollar & Maria Buti. (2018) The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs. Expert Review of Clinical Pharmacology 11:10, pages 999-1030.
Read now
Read now
Maurizio Sessa, Concetta Rafaniello, Cristina Scavone, Annamaria Mascolo, Gabriella di Mauro, Annamaria Fucile, Francesco Rossi, Liberata Sportiello & Annalisa Capuano. (2018) Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?. Expert Opinion on Drug Safety 17:5, pages 457-465.
Read now
Read now
Maurizio Sessa, Claudia Rossi, Annamaria Mascolo, Cristina Scavone, Gabriella di Mauro, Roberto Grassi, Liberata Sportiello, Salvatore Cappabianca & Concetta Rafaniello. (2017) Contrast media-induced nephropathy: how has Italy contributed in the past 30 years? A systematic review. Therapeutics and Clinical Risk Management 13, pages 1463-1478.
Read now
Read now
Articles from other publishers (20)
Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Elena D’Alessio, Imma Izzo, Francesco Rossi, Giuseppe Paolisso, Annalisa Capuano & Liberata Sportiello. (2023) Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL. Frontiers in Pharmacology 14.
Crossref
Crossref
Lia Gvinjilia, Davit Baliashvili, Shaun Shadaker, Francisco Averhoff, Levan Kandelaki, Maia Kereselidze, Tengiz Tsertsvadze, Nikoloz Chkhartishvili, Maia Butsashvili, David Metreveli, Amiran Gamkrelidze & Paige A Armstrong. (2023) Impact of Hepatitis C Virus Infection and Treatment on Mortality in the Country of Georgia, 2015–2020. Clinical Infectious Diseases 77:3, pages 405-413.
Crossref
Crossref
Maria Maddalena Nicoletti, Erminia Crisci, Ciro Pentella, Andrea Cantone, Donatella Ruggiero, Antonietta Anatriello & Cristina Scavone. (2023) Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies. Biologics 3:2, pages 95-115.
Crossref
Crossref
Liberata Sportiello & Annalisa Capuano. (2023) It is the time to change the paradigms of pregnant and breastfeeding women in clinical research!. Frontiers in Pharmacology 14.
Crossref
Crossref
Wenhuo Xie, Xinyan Zhu, Linyao Wang, Jianbin Li & Yu Zhou. (2022) Direct-acting antiviral agent use and gastrointestinal safety in patients with chronic hepatitis C: a pharmacovigilance study based on FDA Adverse Event Reporting System. International Journal of Clinical Pharmacy 45:1, pages 154-162.
Crossref
Crossref
Sumaiah J. Alarfaj, Abdullah Alzahrani, Anfal Alotaibi, Malak Almutairi, Mashael Hakami, Njood Alhomaid, Noori Alharthi, Ghazwa B. Korayem & Abdullah Alghamdi. (2022) The effectiveness and safety of direct-acting antivirals for hepatitis C virus treatment: A single-center experience in Saudi Arabia. Saudi Pharmaceutical Journal.
Crossref
Crossref
Karin Hepp Schwambach & Carine Raquel Blatt. (2021) Effectiveness and potential drug interactions in antiviral therapy for the treatment of chronic hepatitis C: real-life data from a specialized center in southern Brazil. Brazilian Journal of Pharmaceutical Sciences 57.
Crossref
Crossref
Fernanda Bellini Lunardi MICHELS, Ana Cristina de Castro AMARAL, Roberto José de CARVALHO-FILHO, Gustavo de Almeida VIEIRA, Ana Lucia da Silva SOUZA & Maria Lucia Gomes FERRAZ. (2020) HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Arquivos de Gastroenterologia 57:1, pages 45-49.
Crossref
Crossref
Xiaoyun Wang, Xiude Fan, Huan Deng, Xiaoge Zhang, Kun Zhang, Na Li, Qunying Han, Yi Lv & Zhengwen Liu. (2019) Efficacy and safety of glecaprevir/pibrentasvir for chronic hepatitis C virus genotypes 1–6 infection: A systematic review and meta-analysis. International Journal of Antimicrobial Agents 54:6, pages 780-789.
Crossref
Crossref
Daniel Esteban Pino Marín, Pedro Amariles, Jaime Alberto Peláez Alvárez, Gloria Priscilla Alvárez Osorio & Juliana González Ceballos. (2019) Aproximación para establecer y evaluar la relevancia clínica de las interacciones medicamentosas en el tratamiento de pacientes infectados con virus de hepatitis C, revisión estructurada (actualización 2015 – 2017). Revista Colombiana de Gastroenterología 34:2, pages 159-176.
Crossref
Crossref
Marisa Boff Costa, Paulo Dornelles Picon, Guilherme Becker Sander, Hugo Nodarse Cuni, Carmen Valenzuela Silva, Rolando Páez Meireles, Ana Carolina Magalhães Andrade Góes, Nadia Maria Batoreu, Maria de Lourdes de Sousa Maia, Elizabeth Maciel Albuquerque, Denise Cristina de Souza Matos & Pedro Lopez Saura. (2018) Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers. BMC Pharmacology and Toxicology 19:1.
Crossref
Crossref
Maurizio Sessa, Annamaria Mascolo, Cristina Scavone, Ilaria Perone, Annalisa Di Giorgio, Michele Tari, Annamaria Fucile, Antonella De Angelis, Daniel Bech Rasmussen, Magnus Thorsten Jensen, Kristian Kragholm, Francesco Rossi, Annalisa Capuano & Liberata Sportiello. (2018) Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study. Frontiers in Pharmacology 9.
Crossref
Crossref
Sidra Rehman. 2018. Hepatitis C - From Infection to Cure. Hepatitis C - From Infection to Cure.
Ezequiel Ridruejo, Manuel Mendizabal & Marcelo O. Silva. (2018) Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. Hemodialysis International 22:S1.
Crossref
Crossref
Kerry B. Goralski, Matthew A. Ladda & Jenna O. McNeil. 2018. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions. Drug Interactions in Infectious Diseases: Mechanisms and Models of Drug Interactions
163
204
.
Syeda Zainab IlyasRabia TabassumHaroon HamedShafiq Ur RehmanIshtiaq Qadri. (2017) Hepatitis C Virus-Associated Extrahepatic Manifestations in Lung and Heart and Antiviral Therapy-Related Cardiopulmonary Toxicity. Viral Immunology 30:9, pages 633-641.
Crossref
Crossref
Aleksandar Včev, Jelena Jakab, Lucija Kuna & Martina Smolić. 2017. Update on Hepatitis C. Update on Hepatitis C.
Annamaria Mascolo, Cristina Scavone, Maurizio Sessa, Gabriella di Mauro, Daniela Cimmaruta, Valentina Orlando, Francesco Rossi, Liberata Sportiello & Annalisa Capuano. (2017) Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacological Research 123, pages 122-129.
Crossref
Crossref
Maurizio Sessa, Liberata Sportiello, Annamaria Mascolo, Cristina Scavone, Silvia Gallipoli, Gabriella di Mauro, Daniela Cimmaruta, Concetta Rafaniello & Annalisa Capuano. (2017) Campania Preventability Assessment Committee (Italy): A Focus on the Preventability of Non-steroidal Anti-inflammatory Drugs' Adverse Drug Reactions. Frontiers in Pharmacology 8.
Crossref
Crossref
J.‐F. Jiang, J. Sun, J. Shi & X. Liu. (2017) Letter: should direct‐acting antiviral drugs be used concomitantly with chemotherapeutic drugs in hepatitis C virus‐infected patients with cancer?. Alimentary Pharmacology & Therapeutics 45:5, pages 757-758.
Crossref
Crossref